SEEL vs. EVOK, ZVSA, SNGX, RNAZ, PHAS, GTBP, BCEL, REVB, THAR, and LGVN
Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Evoke Pharma (EVOK), ZyVersa Therapeutics (ZVSA), Soligenix (SNGX), TransCode Therapeutics (RNAZ), PhaseBio Pharmaceuticals (PHAS), GT Biopharma (GTBP), Atreca (BCEL), Revelation Biosciences (REVB), Tharimmune (THAR), and Longeveron (LGVN). These companies are all part of the "pharmaceutical preparations" industry.
Evoke Pharma (NASDAQ:EVOK) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
Evoke Pharma received 289 more outperform votes than Seelos Therapeutics when rated by MarketBeat users. However, 66.36% of users gave Seelos Therapeutics an outperform vote while only 62.50% of users gave Evoke Pharma an outperform vote.
Seelos Therapeutics has a consensus target price of $70.00, suggesting a potential upside of 24,121.45%. Given Evoke Pharma's higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than Evoke Pharma.
23.4% of Seelos Therapeutics shares are owned by institutional investors. 6.1% of Evoke Pharma shares are owned by insiders. Comparatively, 5.4% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Evoke Pharma has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.
Evoke Pharma has a net margin of -150.43% compared to Evoke Pharma's net margin of -1,719.56%. Evoke Pharma's return on equity of 0.00% beat Seelos Therapeutics' return on equity.
Evoke Pharma has higher revenue and earnings than Seelos Therapeutics.
In the previous week, Evoke Pharma and Evoke Pharma both had 2 articles in the media. Seelos Therapeutics' average media sentiment score of 0.33 beat Evoke Pharma's score of -0.27 indicating that Evoke Pharma is being referred to more favorably in the media.
Summary
Evoke Pharma and Seelos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Seelos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seelos Therapeutics Competitors List
Related Companies and Tools
